Bright minds biosciences appoints drug development executive mark a. smith m.d.

-- dr. smith is a 20-year pharmaceutical industry veteran with extensive central nervous system (“cns”) clinical development expertise -- vancouver, british columbia, nov. 23, 2022 (globe newswire) -- bright minds biosciences (“bright minds,” “bmb” or the “company”) (nasdaq: drug) (cse: drug), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that mark a. smith m.d., ph.d. will join the company as chief medical officer, effective december 1, 2022. the company also announces that dr. revati shreeniwas' engagement with bright minds as chief medical officer has been terminated.
DRUG Ratings Summary
DRUG Quant Ranking